However, resistance and adaptation of cancer patients and, in general, the lack of the expected benefits of anti‐VEGF therapies have underlined the need to focus on a next generation of antiangiogenic drugs based on pathways alternative to VEGF 28. The gene discussed is VEGFA; the disease is cancer.